Ergomed sees FY earnings 'materially ahead' of market expectations
16th May 2019 09:05
(Sharecast News) - Ergomed said on Thursday that full-year revenue and earnings are set to be "materially" ahead of current market expectations following strong trading year-to-date.
Read moreThree AIM firms celebrate Queen's Award for Enterprise wins
23rd Apr 2019 10:33
(Sharecast News) - Three firms trading on London's AIM market were celebrating wins in the Queen's Award for Enterprise on Tuesday, with Inspiration Healthcare, Ergomed and Oxford BioDynamics all picking up the accolades.
Read moreErgomed taps former TFS executive for chief commercial officer
1st Apr 2019 08:46
(Sharecast News) - Pharmaceutical services firm Ergomed appointed former TFS International global sales and marketing head Roy Ovel as its next chief commercial officer on Monday.
Read moreWednesday broker round-up
19th Sep 2018 13:13
(Sharecast News) - PureCircle: Kepler Cheuvreux downgrades to hold with a target price of 325p.
Read moreErgomed reports positive results from insomnia drug trial
6th Feb 2017 09:24
(ShareCast News) - AIM-listed pharma company Ergomed on Monday reported positive top-line results from a Phase II clinical trial of Lorediplon in patients with insomnia with its co-development partner Ferrer. The company said both 5 and 10mg Lorediplon met the primary endpoint with "high statistical
Read moreErgomed buys drug safety and regulatory consultancy for £4m
29th Nov 2016 09:07
(ShareCast News) - AIM-listed pharmaceutical Ergomed has bought Prague-based European PharmInvent Services for €4.8m (£4.1m), in order to grow its services business. The acquisition of PharmInvent, a drug safety and regulatory consultancy, will expand the company's pharmacovigilance division, PrimeV
Read moreErgomed to benefit from Zoptrex Australasia deal
14th Oct 2016 11:35
(ShareCast News) - Specialised pharmaceutical services company Ergomed announced on Friday that its co-development partner, Aeterna Zentaris, has signed an additional licensing agreement for Zoptrex. The AIM-traded firm said Aeterna Zentaris signed an exclusive license agreement on Wednesday with Sp
Read moreErgomed wins two licenses for cancer drug Zoptrex
2nd Sep 2016 09:27
(ShareCast News) - Pharmaceutical service provider Ergomed's development partner Aeterna Zentaris, won two licensing deals for its cancer drug Zoptrex gaining new territory in Southeast Asia and the Middle East. In July 2016 Aeterna Zentaris signed a license agreement with affiliates of Orient EuroP
Read moreErgomed buys two German service companies
13th Jun 2016 14:03
(ShareCast News) - Ergomed, a British pharmaceutical development services company, said on Monday, it had bought two German service providers to complement and enhance its existing capabilities, and increase its presence in Germany. The company acquired Dr. Oestreich + Partner GmbH (O+P), a full ser
Read moreErgomed doubles profits as contract revenues increase
29th Sep 2015 14:03
(ShareCast News) - Ergomed has doubled its half year gross profit after increasing revenues from its clinical studies and pharmacovigilance contracts. The AIM-listed company, which provides specialised services to the pharmaceutical industry and develops new drugs, posted its half year results to 30
Read moreErgomed appoints former consultant as chief business officer
2nd Jul 2015 08:31
Pharmaceutical services company Ergomed has hired Eli Lilly executive Andrew Mackie as chief business officer. Mackie would also take on the board role of executive director, Ergomed said in an announcement. The veteran pharmaceutical executive worked with Ergomed as a consultant previously, and ha
Read moreErgomed chosen by Aeterna Zentaris for Phase 3 study
25th Jun 2015 13:42
Ergomed said on Thursday that it has been chosen by Aeterna Zentaris Inc to manage the new, confirmatory Phase 3 clinical study to demonstrate the efficacy of its Macrilen product for evaluating adult growth hormone deficiency. The Phase 3 clinical study will be conducted as a two-crossover study wi
Read moreErgomed revenue jumps, remains confident on strong backlog of signed contracts
25th Mar 2015 15:26
Drug development services provider Ergomed cited contracts won during the year as the main revenue driver. In its first annual report since floating last July, the group said revenue surged 40% to £21.2m on the back of £26.8m of service contracts secured during the year. A number of one-off charges
Read more